Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QUOTED. Jan. 28, 2019. Mylene Yao.

Executive Summary

Silicon Valley-based start-up Univfy is looking to help couples attain easier access to in vitro fertilization treatment and financing. Univfy co-founder and CEO Mylene Yao says the company has developed a business-to-business machine-learning-platform that allows IVF clinics to accurately predict the chances of IVF success rate for individual couples. See what she said about it here.

"Doctors mostly thought that age is the main determinant [for a woman's IVF success] and it's very important biologically, but it only contributes 50% of the prediction. If you're telling a woman her chances of IVF success are just based on age, you're missing half of the story." –Mylene Yao, co-founder and CEO, Univfy

Click here for a free trial of Medtech Insight

 
Advertisement

Related Content

Start-Up Spotlight: Raising The Odds For IVF Success, Univfy Brings Algorithms To Fertility Clinics

Topics

Advertisement
UsernamePublicRestriction

Register

MT124543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel